{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+insulin&page=2",
    "query": {
      "intervention": "Intravenous insulin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 135,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+insulin&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+insulin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T13:01:45.476Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02556918",
      "title": "Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Regular Human Insulin",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "Supplemental insulin (Insulin lispro)",
          "type": "DRUG"
        },
        {
          "name": "Supplemental insulin (Insulin aspart)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 202,
      "start_date": "2016-01",
      "completion_date": "2018-11-06",
      "has_results": true,
      "last_update_posted_date": "2019-12-23",
      "last_synced_at": "2026-09-30T13:01:45.476Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02556918"
    },
    {
      "nct_id": "NCT01819844",
      "title": "Inpatient Closed-loop Glucose Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Closed-loop blood glucose control",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 12,
      "start_date": "2013-03",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-12-12",
      "last_synced_at": "2026-09-30T13:01:45.476Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01819844"
    },
    {
      "nct_id": "NCT00949663",
      "title": "Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Glucose-dependent Insulinotropic Polypeptide (GIP)",
          "type": "DRUG"
        },
        {
          "name": "Xenin-25",
          "type": "DRUG"
        },
        {
          "name": "Glucose-dependent Insulinotropic Polypeptide plus Xenin-25",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 38,
      "start_date": "2009-10",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2014-07-22",
      "last_synced_at": "2026-09-30T13:01:45.476Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00949663"
    },
    {
      "nct_id": "NCT06643351",
      "title": "Intrapartum Glucose Control and Risk of Neonatal Hypoglycemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gestational Diabetes Mellitus in Pregnancy",
        "Pregestational Diabetes Mellitus",
        "Neonatal Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "Standard Intrapartum Glucose Target Range",
          "type": "OTHER"
        },
        {
          "name": "Liberalized Intrapartum Glucose Target Range",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 169,
      "start_date": "2024-12-03",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-09-30T13:01:45.476Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06643351"
    },
    {
      "nct_id": "NCT00433173",
      "title": "Insulin Sensitivity in Men With the Metabolic Syndrome",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "intravenous glucose tolerance test",
          "type": "PROCEDURE"
        },
        {
          "name": "testosterone",
          "type": "DRUG"
        },
        {
          "name": "anastrozole",
          "type": "DRUG"
        },
        {
          "name": "goserelin acetate implant",
          "type": "DRUG"
        },
        {
          "name": "aerobic capacity (VO2 Max)",
          "type": "PROCEDURE"
        },
        {
          "name": "MRI",
          "type": "PROCEDURE"
        },
        {
          "name": "muscle biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "measurement of resting metabolic rate (energy expenditure)",
          "type": "PROCEDURE"
        },
        {
          "name": "Dual energy x-ray absorptiometry",
          "type": "PROCEDURE"
        },
        {
          "name": "Fasting oral glucose tolerance test",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "50 Years to 75 Years · Male only"
      },
      "enrollment_count": 72,
      "start_date": "2006-05",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2010-03-02",
      "last_synced_at": "2026-09-30T13:01:45.476Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00433173"
    },
    {
      "nct_id": "NCT00279305",
      "title": "Rituximab in New Onset Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Anti-CD20 (rituximab)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "8 Years to 45 Years"
      },
      "enrollment_count": 87,
      "start_date": "2005-08",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2020-05-06",
      "last_synced_at": "2026-09-30T13:01:45.476Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00279305"
    },
    {
      "nct_id": "NCT01186003",
      "title": "Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Detemir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "19 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2010-08",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2021-12-07",
      "last_synced_at": "2026-09-30T13:01:45.476Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01186003"
    },
    {
      "nct_id": "NCT06883344",
      "title": "Automated Insulin for Management of Intrapartum Glycemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 1 Diabetes (T1D)",
        "Pregnancy",
        "Pre-Gestational Diabetes"
      ],
      "interventions": [
        {
          "name": "Automated insulin delivery (AID) system",
          "type": "DEVICE"
        },
        {
          "name": "Intravenous (IV) insulin",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 150,
      "start_date": "2025-12-05",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-09-30T13:01:45.476Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06883344"
    },
    {
      "nct_id": "NCT00460499",
      "title": "Improving Outcomes In Diabetic Patients During CABG Surgery By Optimizing Glycemic Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glycemic Control"
      ],
      "interventions": [
        {
          "name": "A IV Insulin drip",
          "type": "DRUG"
        },
        {
          "name": "B Low Dose GIK",
          "type": "DRUG"
        },
        {
          "name": "C High Dose GIK",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "American Heart Association",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 250,
      "start_date": "2004-07",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-06-23",
      "last_synced_at": "2026-09-30T13:01:45.476Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00460499"
    },
    {
      "nct_id": "NCT00882050",
      "title": "Intravenous Exenatide (Byetta) During Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Euglycemia",
        "Hypoglycemia",
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Exenatide 0.27 ng/kg/min",
          "type": "DRUG"
        },
        {
          "name": "Exenatide 0.41 ng/kg/min",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2009-03",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2022-01-21",
      "last_synced_at": "2026-09-30T13:01:45.476Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00882050"
    }
  ]
}